









Markets
/
Stocks
/
nasdaq-avtx
/

Avalo Therapeutics Inc

AVTX

15.420USD

-1.030-6.26%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

167.11MMarket Cap

LossP/E TTM



Avalo Therapeutics Inc

15.420

-1.030-6.26%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Avalo Therapeutics Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Avalo Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

170 / 407

Overall Ranking

302 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

33.714

Target Price

+104.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Avalo Therapeutics Inc Highlights

StrengthsRisks

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Growing

The company is in a growing phase, with the latest annual income totaling USD 441.00K.

Overvalued

The company’s latest PE is 1.19, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.96M shares, increasing 0.90% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 692.64K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.70, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.70

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Avalo Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.46, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 1.19, which is 19.19% below the recent high of 1.41 and 227.10% above the recent low of -1.51.

Score

Industry at a Glance

Previous score

7.46

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 170/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.89, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Avalo Therapeutics Inc is 35.00, with a high of 48.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

33.714

Target Price

+104.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Avalo Therapeutics Inc

AVTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 2.36, which is lower than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 18.82 and the support level at 12.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.42

Change

-0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.707

Neutral

RSI(14)

49.120

Neutral

STOCH(KDJ)(9,3,3)

13.828

Sell

ATR(14)

1.678

Low Volatility

CCI(14)

-137.138

Sell

Williams %R

96.962

Oversold

TRIX(12,20)

1.263

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

16.532

Sell

MA10

17.268

Sell

MA20

16.287

Sell

MA50

13.498

Buy

MA100

10.151

Buy

MA200

8.116

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 68.14%, representing a quarter-over-quarter decrease of 16.90%. The largest institutional shareholder is The Vanguard, holding a total of 692.64K shares, representing 5.27% of shares outstanding, with 232.62% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

1.03M

-0.83%

Nantahala Capital Management, LLC

995.00K

+10.56%

OrbiMed Advisors, LLC

967.00K

RA Capital Management, LP

932.97K

-3.52%

The Vanguard Group, Inc.

Star Investors

166.94K

Affinity Asset Advisors LLC

607.87K

-7.50%

Point72 Asset Management, L.P.

Star Investors

588.63K

Deep Track Capital LP

567.10K

-34.05%

Crutcher (Patrick J)

549.47K

TCG Crossover Management, LLC

483.00K

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.31, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.